Literature DB >> 16400029

Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression.

Marina Simian1, Alfredo Molinolo, Claudia Lanari.   

Abstract

Proteolytic activity and remodeling of the extracellular matrix are important players in tumor progression. However, to date the role of the extracellular matrix in tumor regression remains unresolved. To address this, we used a progesterone-dependent in vivo mouse mammary tumor line, C4-HD, which regresses in response to hormone therapy. Within the first 72 hours of treatment, massive apoptosis was accompanied by changes in the staining patterns of laminin and collagens I, III, and IV. We thus hypothesized that an increase in matrix metalloproteinase (MMP) activity could be involved in this process. This indeed was the case as the activities of MMP-2, -9, and -3 increased in regressing tumors, coinciding with the peak of apoptosis. Moreover, cell-cell interactions were disrupted during early hours of regression with E-cadherin levels reduced and fragmentation products detected during regression. Analysis of beta-catenin revealed that although total levels within the tissue did not change, this molecule switched from being involved in cell-cell adhesion in the growing tumor to being expressed in the reactive stroma during regression. Our data provide a novel role for proteolytic activity in tumor regression and question the underlying principle for using MMP inhibitors in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16400029      PMCID: PMC1592671          DOI: 10.2353/ajpath.2006.050012

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

Review 1.  How matrix metalloproteinases regulate cell behavior.

Authors:  M D Sternlicht; Z Werb
Journal:  Annu Rev Cell Dev Biol       Date:  2001       Impact factor: 13.827

Review 2.  New functions for the matrix metalloproteinases in cancer progression.

Authors:  Mikala Egeblad; Zena Werb
Journal:  Nat Rev Cancer       Date:  2002-03       Impact factor: 60.716

Review 3.  The microenvironment of the tumour-host interface.

Authors:  L A Liotta; E C Kohn
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

4.  Posttranslational truncation and inactivation of human E-cadherin distinguishes prostate cancer from matched normal prostate.

Authors:  M G Rashid; M G Sanda; C J Vallorosi; J Rios-Doria; M A Rubin; M L Day
Journal:  Cancer Res       Date:  2001-01-15       Impact factor: 12.701

Review 5.  Matrix metalloproteinase inhibitors and cancer: trials and tribulations.

Authors:  Lisa M Coussens; Barbara Fingleton; Lynn M Matrisian
Journal:  Science       Date:  2002-03-29       Impact factor: 47.728

Review 6.  Recent trends in breast cancer incidence and mortality.

Authors:  James V Lacey; Susan S Devesa; Louise A Brinton
Journal:  Environ Mol Mutagen       Date:  2002       Impact factor: 3.216

7.  MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.

Authors:  L M Coussens; C L Tinkle; D Hanahan; Z Werb
Journal:  Cell       Date:  2000-10-27       Impact factor: 41.582

8.  Epithelial to mesenchymal transition in human breast cancer can provide a nonmalignant stroma.

Authors:  Ole William Petersen; Helga Lind Nielsen; Thorarinn Gudjonsson; René Villadsen; Fritz Rank; Erik Niebuhr; Mina J Bissell; Lone Rønnov-Jessen
Journal:  Am J Pathol       Date:  2003-02       Impact factor: 4.307

9.  The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells.

Authors:  M Simian; Y Hirai; M Navre; Z Werb; A Lochter; M J Bissell
Journal:  Development       Date:  2001-08       Impact factor: 6.868

10.  Normal and tumor-derived myoepithelial cells differ in their ability to interact with luminal breast epithelial cells for polarity and basement membrane deposition.

Authors:  Thorarinn Gudjonsson; Lone Rønnov-Jessen; René Villadsen; Fritz Rank; Mina J Bissell; Ole William Petersen
Journal:  J Cell Sci       Date:  2002-01-01       Impact factor: 5.285

View more
  10 in total

1.  Decreased metastatic phenotype in cells resistant to aminolevulinic acid-photodynamic therapy.

Authors:  Adriana Casas; Gabriela Di Venosa; Silvia Vanzulli; Christian Perotti; Leandro Mamome; Lorena Rodriguez; Marina Simian; Angeles Juarranz; Osvaldo Pontiggia; Tayyaba Hasan; Alcira Batlle
Journal:  Cancer Lett       Date:  2008-07-26       Impact factor: 8.679

2.  MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis.

Authors:  Helen Williams; Jason L Johnson; Christopher L Jackson; Stephen J White; Sarah J George
Journal:  Cardiovasc Res       Date:  2010-02-05       Impact factor: 10.787

3.  Responsiveness to PI3K and MEK inhibitors in breast cancer. Use of a 3D culture system to study pathways related to hormone independence in mice.

Authors:  Maria Laura Polo; Maria Victoria Arnoni; Marina Riggio; Victoria Wargon; Claudia Lanari; Virginia Novaro
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

4.  Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth.

Authors:  Cecilia J Proietti; Cinthia Rosemblit; Wendy Beguelin; Martín A Rivas; María Celeste Díaz Flaqué; Eduardo H Charreau; Roxana Schillaci; Patricia V Elizalde
Journal:  Mol Cell Biol       Date:  2008-12-22       Impact factor: 4.272

5.  Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice.

Authors:  María Paula Roberti; Juan Martín Arriaga; Michele Bianchini; Héctor Ramiro Quintá; Alicia Inés Bravo; Estrella Mariel Levy; José Mordoh; María Marcela Barrio
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

6.  The collagenase-1 (MMP-1) gene promoter polymorphism - 1607/2G is associated with favourable prognosis in patients with colorectal cancer.

Authors:  A Hettiaratchi; N J Hawkins; G McKenzie; R L Ward; J E Hunt; D Wakefield; N Di Girolamo
Journal:  Br J Cancer       Date:  2007-02-20       Impact factor: 7.640

Review 7.  Antiprogestins in gynecological diseases.

Authors:  Alicia A Goyeneche; Carlos M Telleria
Journal:  Reproduction       Date:  2014-09-24       Impact factor: 3.906

8.  Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer development.

Authors:  Martin A Rivas; Leandro Venturutti; Yi-Wen Huang; Roxana Schillaci; Tim Hui-Ming Huang; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2012-05-14       Impact factor: 6.466

9.  Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.

Authors:  María C Díaz Flaqué; Natalia M Galigniana; Wendy Béguelin; Rocío Vicario; Cecilia J Proietti; Rosalía Russo; Martín A Rivas; Mercedes Tkach; Pablo Guzmán; Juan C Roa; Esteban Maronna; Viviana Pineda; Sergio Muñoz; María Mercogliano; Eduardo H Charreau; Patricio Yankilevich; Roxana Schillaci; Patricia V Elizalde
Journal:  Breast Cancer Res       Date:  2013-12-17       Impact factor: 6.466

10.  The effectiveness of nano chemotherapeutic particles combined with mifepristone depends on the PR isoform ratio in preclinical models of breast cancer.

Authors:  Gonzalo Sequeira; Silvia I Vanzulli; Paola Rojas; Caroline Lamb; Lucas Colombo; Maria May; Alfredo Molinolo; Claudia Lanari
Journal:  Oncotarget       Date:  2014-05-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.